Introduction
Transcatheter Aortic Valve Implantation (TAVI) is a welldescribed treatment for symptomatic calcific severe aortic stenosis. However, TAVI technology is being increasingly used around the world to treat selected cases of severe aortic regurgitation (AR). One of the main limitations of using TAVI technology for AR is the lack of calcification, which is common in such cases. This makes anchoring of a TAVI prosthesis to the aortic annulus difficult and risks displacement or embolization. However, with the availability of recapturable and repositionable TAVI technologies, these limitations have been overcome to a large extent. This is the first Corevalve Evolut R device that was used in India and the first TAVI to treat AR in India.
Case report
A 45-year-old man, awaiting liver transplantation, suffered aortic valve (AV) endocarditis 9 months previously, which was i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 4 -s 7 a r t i c l e i n f o Echocardiogram showed severe AR and a 1 cm highly mobile hyperechoic mass attached to his AV (Fig. 1) . Gated cardiac CT scan showed unobstructed coronaries, no calcification of the aortic root or AV, and good caliber peripheral vessels for a transfemoral delivery of TAVI prosthesis. The plan was to squash the vegetation along with the valve leaflet behind the TAVI prosthesis using a repositionable TAVI device. A Corevalve Evolut R was chosen, which has the capability of resheathing and recapturing the device and thereby allowing redeployment if optimal positioning and outcome was not achieved.
As embolization of the chronic vegetation was a major concern; two carotid artery filters were positioned, one in each internal carotid artery before crossing the AV (Fig. 2) . The TAVI procedure was performed in the standard way using 3D transesophageal echocardiogram (TOE) guidance. During the valve deployment, the valve slipped out of the annulus twice into the ascending aorta due to lack of calcification and hyperdynamic left ventrice contraction. The Evolut R device allowed resheathing and repositioning on these occasions. During these attempts, the vegetation was monitored throughout with TOE and the vegetation did not embolize. At the third attempt, rapid ventricular pacing was undertaken, which completely abolished cardiac output and the valve was released at the optimal position trapping the vegetation within the aortic sinus along with the aortic leaflet (Figs. 3 and 4) . There was no AR on aortography and on TOE. There were no complications and the patient was discharged home on day 3 of the procedure. The patient was discharged on Clopidogrel 75 mg OD. The patient subsequently had a successful liver transplantation after stopping Clopidogrel for five days before i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 4 -s 7 i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 4 -s 7 surgery and substituting it with low molecular weight heparin until the day before liver transplantation. He was discharged after transplantation with Clopidogrel 75 mg OD. At two months follow-up, the patient was asymptomatic with normal TAVI prosthetic function on echocardiogram with no AR and no visible vegetation (Fig. 5) . The patient had no evidence of infection or active inflammation.
Discussion
This case demonstrates the feasibility and acute outcome of TAVI for AR and the benefit of having a recapturable and repositionable TAVI prosthesis. It also has shown for the first time that sterile vegetations with appropriate anatomy may not be an absolute contraindication for TAVI. To our knowledge, this is the first human case to demonstrate this.
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